(RTTNews) - Swiss drug major Roche Group (RHHBY), at its Pharma Day 2024, said it expects sales momentum to continue into 2025, with strong growth by both divisions of Pharma and Diagnostics. The ...

Basel, Switzerland and Vacaville, US, 1 October 2024 – Lonza, one of the world’s largest healthcare development and manufacturing organizations, today announced it has completed its acquisition of the ...

Roche is planning to launch 13 medicines by the end of the decade and cut research costs for new drugs by a fifth, according to a strategy update on Monday.

Roche is narrowing its pipeline to 11 disease areas and continuing to invest in a targeted way, said Teresa Graham, chief ...

Roche said it plans to focus on five key therapeutic areas as part of its new pharma strategy through 2030. The company will prioritize work in the areas of neurology, oncology and hematology, ...

The Temperature-Activated Generation of Signal (TAGS) technology was developed by Roche for its high-throughput PCR-based instruments.

Roche’s current pharmaceutical portfolio will deliver growth through at least 2027, the company said. Schinecker has already ...

Typically, when clinicians assess a certain group of targets first ... diagnostic results per well - all out of a single test kit. Roche’s new TAGS technology overcomes the technical limitations ...

Positive phase III results for Roche’s Gazyva/Gazyvaro show superiority to standard therapy alone in people with lupus ...

Chinese Vice Premier He Lifeng met with Severin Schwan chairman of the Board of Directors of Roche Group in Beijing on Friday evening He also a me ...

Basel, 24 September 2024 - Roche (SIX: RO, ROG ... which is especially important when a common group of symptoms can be related to more than one pathogen. “Many respiratory illnesses share ...

New TAGS (Temperature-Activated Generation of Signal) technology enables up to 15 targets to be detected simultaneously in a ...